Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate the efficacy and safety of the combination of pemetrexed and
gemcitabine in heavily pre-treated, chemotherapy resistant colorectal cancer patients with
KRAS mutations.